Pangaea Data enters artificial intelligence collaboration with Alexion to help improve detection of Hypophosphatasia in adults

June 9^th 2025 London (UK) and South San Francisco, CA (USA) 

Pangaea Data Limited (“Pangaea Data”), provider of a novel Artificial Intelligence (AI)-driven  platform to improve detection of hard-to-diagnose conditions in a privacy-preserving and  scalable manner, has entered into a collaboration agreement with Alexion, AstraZeneca  Rare Disease (“Alexion”). This collaboration aims to develop, clinically validate, and obtain  regulatory approval for an Artificial Intelligence Clinical Decision Support System (AI-CDSS)  designed to improve detection of Hypophosphatasia (HPP) in adults. As part of this  collaboration, Alexion will provide the funding for the development of the AI-CDSS. 

HPP is a rare, inherited disorder that results from Alkaline phosphatase (ALP) deficiency, or  low ALP, which is associated with reduced bone mineralisation, impaired energy  metabolism, and compromised neurotransmitter function [1,2.]. The manifestations of HPP  can be wide-ranging, and the disease often remains undiagnosed or misdiagnosed due to its  diverse and non-specific symptoms. By leveraging AI and clinical guidelines, the AI-CDSS  developed by Pangaea Data in collaboration with Alexion will seek to improve the detection  of HPP in adults based on information from electronic health records (EHRs). With improved  detection, adults living with HPP could receive a timelier diagnosis and clinical intervention,  ultimately achieving better health outcomes.  

Dr. Vibhor Gupta, Founder and CEO, Pangaea Data said: “We are excited to partner with  Alexion. The scalable application of Pangaea’s AI platform to detect hard-to-diagnose  conditions, like HPP in adults, has the potential to benefit both patients and clinicians by  enabling accurate and timely diagnosis thereby unlocking the full potential of precision  medicine.” 

“Adults living with a rare disease such as HPP often wait years to receive an accurate  diagnosis because of the complex nature, varied symptoms and limited awareness of the  condition, a journey that is inherently inequitable,” said Seng H. Cheng, Senior Vice  President, Head of Research and Product Development, Alexion. “We are committed to  supporting potential solutions to help enable accurate and timely diagnoses which can make 

a critical impact in the ability to treat patients, and we look forward to advancing this  collaboration with Pangaea Data.”